Topiramate for Binge Eating Disorder
Topiramate can be used off-label to treat binge eating disorder in adults, with evidence showing significant reductions in binge frequency and weight loss, though it is not FDA-approved for this indication.
FDA Approval Status and Off-Label Use
Topiramate is FDA-approved only for epilepsy and migraine prophylaxis 1. However, topiramate is widely used off-label by clinicians for binge eating disorder (BED), with prospective randomized placebo-controlled trials demonstrating efficacy 2. The AGA 2022 guidelines explicitly acknowledge that "topiramate has been used to manage some eating disorders, although most published effects are case series or case reports" 2.
Evidence for Efficacy
Binge Eating Reduction
- Topiramate significantly reduces binge eating episodes by approximately 1.3-1.6 episodes per week compared to placebo 3
- Reduces binge eating days by approximately 1 day per week (MD = -0.98; 95% CI = -1.80 to -0.16) 3
- Achieves binge eating remission in 58% of patients versus 29% with placebo (p < .001) 4
- The most recent network meta-analysis (2026) found topiramate comparable to lisdexamfetamine in reducing binge frequency (MD -1.63 vs -1.61) 5
Weight Loss Benefits
- Produces the greatest weight loss among BED medications at approximately 4.5-5.5 kg 5, 3, 4
- Weight reduction: MD = -4.91 kg (95% CI = -6.42 to -3.41) compared to placebo 3
- BMI reduction of approximately 1.6 kg/m² 4
Dosing Protocol
Start low and titrate slowly to minimize adverse effects:
- Starting dose: 25 mg daily (or less, 1-3 mg/kg/day in some protocols)
- Titration: Increase by 25-50 mg weekly
- Target therapeutic dose: 125-200 mg daily 6
- Maximum studied dose: 200-400 mg daily 7
- Duration to assess response: 12 weeks minimum
The modeling study suggests 125 mg daily is the minimum dose needed for marked reduction in binge eating frequency 6.
Safety Considerations and Monitoring
Common Adverse Effects
- Paresthesias (most common)
- Cognitive impairment ("word-finding difficulties")
- Somnolence
- Nausea
- Taste perversion
- Weight loss (desired in BED context)
Serious Safety Concerns
Topiramate has higher discontinuation rates for safety reasons compared to placebo (RR = 1.90; 95% CI = 1.13-3.18) 3. Adverse events led to discontinuation in 16% of topiramate patients versus 8% on placebo 4.
Required Monitoring
- Serum bicarbonate levels (risk of metabolic acidosis due to carbonic anhydrase inhibitor properties)
- Kidney stone risk with prolonged use (hypercalciuria, hypocitraturia)
- Pregnancy testing - topiramate is highly teratogenic; contraception is mandatory in women of childbearing potential
Contraindications
- Pregnancy or inadequate contraception in women of childbearing potential
- History of significant nephrolithiasis
- Untreated hyperthyroidism
- Within 14 days of MAOI use
- Caution in patients with history of cognitive impairment
Clinical Decision Algorithm
Use topiramate for BED when:
- Patient has BED with comorbid obesity (BMI ≥30 or ≥27 with complications)
- Lisdexamfetamine (FDA-approved for BED) is unavailable, unaffordable, or contraindicated
- Patient has comorbid migraines (dual benefit)
- Patient can comply with contraception requirements (if applicable)
- Patient accepts cognitive side effect risks
Avoid topiramate when:
- Patient is pregnant, planning pregnancy, or unable to use reliable contraception
- History of kidney stones
- Baseline cognitive impairment that would be worsened
- Patient prioritizes avoiding cognitive side effects over weight loss
Comparative Context
While lisdexamfetamine is the only FDA-approved medication for BED, topiramate offers comparable efficacy for binge reduction with superior weight loss 5. The 2022 AGA guidelines note topiramate's use in eating disorders but emphasize the limited long-term data (most trials <12 months) 2.
Topiramate ranks as a second-line option for BED when FDA-approved options are not suitable, with the understanding that it requires careful patient selection, slow titration, appropriate monitoring, and informed consent regarding off-label use 7.
Key Clinical Pitfalls
- Starting dose too high or titrating too quickly increases dropout rates
- Failing to counsel about teratogenicity in women of childbearing age
- Not monitoring bicarbonate levels long-term
- Expecting immediate results - allow 12 weeks to assess response
- Ignoring cognitive complaints - these are common and may necessitate dose reduction or discontinuation